The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Good point DugWalker Thanks
I know he’s a significant shareholder but the optics don’t look good. Does anyone think he should have held on? “ Stephen Diggle, has sold 115,000 Ordinary Shares of 1 pence each ("shares") at an average price of 45.2p”.
To me it doesn’t show any faith he would have better returns by continuing to hold them.
Nice one JT (& chatGPT). Very happy with that 😁
Yn sicr gobeithio 👍🏻
Thanks for the info Penstock
Been away at a funeral in wales so only just back and catching up.
Hi Penstock I’d be interested in your views on todays RNS? Where do you see them putting the profit? Are dividends back on the horizon? Or is it an uptick in SP until profits are consistently good and the costs stop biting.
Next ones*
Mustang just wondering where you found the information on when the shares get sold? (Might have timed my last top up a bit better and more importantly my next one! If you can point me towards that info).
No wonder they delayed them! 😠
They’re out!
Thanks for the link - works well
Added a small top up 4529 shares just to round up my holding.
Any way the delay could be good news? 🧐 at best I’d guess neutral at worse they are trying to delay to sweeten it with the latest production figures (never mind we are back on track?). I suppose we will know soon enough. GLA
The actual words Al used are at 11:30 - the spacer can affect the rate at which drugs are released
Hi Bella & BV, this was when Al reached on about slide 13 (lucky for some?) and it’s what he was saying could be added to the formulation - it wasn’t being used with AVA6000 but I took it this could be added in.
The other point I noticed is when he talked about the mechanism of the Pre|CISION platform he mentioned they could also include a ‘spacer’ that could control the release of the active drug into the tumour environment. So I see this as potentially much higher doses allowable that would target the cancer by slow release of therapy at the MTD 🧐 without need to return for repeat injections?
Love the positivity Penstock but have to agree with Corryvreckan1 that this is “not a good look when they have had 6 months to prepare them and stated they were to be expected today just 2 weeks ago”.
An RNS could drop at any time. Particularly if they are in discussions with any big Pharma companies to be ready to scale up production of AVA6000. If shareholders are weary of the price not reflecting the results they might well be tempted to accept a (relatively low ball offer at 2/3 x the current share price.
e.g. “ THIS IS AN ANNOUNCEMENT UNDER RULE 2.4 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CODE. THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER MIGHT BE MADE”?
While we wait for the rest of the market to catch up it’s simply a good opportunity to add a few more (which is what I’ve done this morning). GLA
Timster It will be interesting to see how they answer that question (what are avacta's plans to scale up production when AVA6000 replaces dox for standard of care). I’ve already submitted my questions to do with plans for AA if the parallel study demonstrates any repeats of the reduction in STS tumour size.